

BIO-GENE SUBMITS TWO NEW INTERNATIONAL PATENT APPLICATIONS

- **First patent covers use of Beta-triketones to control resistant pest populations**
- **Second patent covers use of Beta-triketones in combination with other chemistry to control pests**
- **Beta-triketones are a naturally occurring class of chemicals, and form the basis for Bio-Gene's Flavocide™ compound**
- **Successful patent grant will provide protection until at least 2038.**

Bio-Gene Technology Limited (ASX: BGT, "Bio-Gene" or "the Company"), an agtech development company enabling the next generation of novel insecticides to address insecticide resistance, is pleased to announce the submission of two new international patent applications.

These applications are based on novel inventions generated by the company over the past 18 months with respect to the role of its technology against various resistant pest populations and compelling data relating to use of its technology in combination with existing chemistries.

The submissions, entitled "*Pest Management*" and "*Control of Resistant Pests*", will cover the family of chemistry known as Beta-triketones when used in combination with other pesticides or when used to control insecticide resistant populations of pests.

These patent applications reserve the right to file applications in all major countries around the world. Successful grants will provide protection for the technologies until at least July 2038.

Richard Jagger, Bio-Gene's CEO commented: "We are delighted to be able to make these submissions, based on data we have been obtaining from our research over the past 18 months. These are significant milestones in the development of our Intellectual Property (I.P.) and value proposition. The extended period of protection offered by these patents will create significant advantages for our customers as they develop new and novel products for the marketplace."

The ongoing development of I.P. for the company's technology platform is a key component of the Company's strategic plan to deliver value to its customers and shareholders.

In addition to filing these patents, the company has been able to accumulate specific I.P. relating to the manufacture of its lead molecules Flavocide™ and Qcide™. Bio-Gene intends to continue to develop value-adding I.P. surrounding its technology and to file further patent applications in the future.

ENDS

For further information, please contact:

Bio-Gene Technology Limited:

Richard Jagger
Chief Executive Officer
P: 03 9628 4178
E: bgt.info@bio-gene.com.au

Roger McPherson
CFO & Company Secretary
P: 03 9628 4178
E: bgt.info@bio-gene.com.au

Media/investor relations:

Ben Walsh or Kyahn Williamson
WE Buchan
T: 03 9866 4722
E: bio-gene@we-buchan.com

Bio-Gene Technology Limited

ABN: 32 071 735 950

Suite 1, Level 6, 50 Queen St, Melbourne, VIC 3000

About Bio-Gene Technology Limited

Bio-Gene is an Australian agtech development company enabling the next generation of novel insecticides to address the global problems of insecticide resistance and toxicity. Its novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across animal health and crop protection, as well as in public health, and in consumer applications.

The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions.